Robert Azelby
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
ADC Therapeutics Announces $86.6M Financing and Loan Amendments. ADC Therapeutics has secured $86.6 million through a private placement of 12.9 million shares at $1.42 each, along with warrants for 48.1 million shares. The company also amended its existing loan and royalty agreements. This capital raise provides additional liquidity to support operations, occurring while the stock trades near the top of its recent range.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Cardinal Health Hits Record Highs as Sector Strength Continues. Cardinal Health's stock has reached record highs, outperforming the broader market as the healthcare sector shows strong momentum. In corporate news, Senior Vice President Shane Abeyratne has joined the Customer Experience Advisory Board of Level AI. Meanwhile, market observers are looking ahead to the company's upcoming Q1 2027 earnings report and its position as a defensive option in the current economic environment.
Transaction History
| TNGX | ▲ Buy | Grant | 5,740 | $0 | 6/19/2026 | View on chart |
| ADCT | ▼ Sell | Tax Withholding | 12,600 | $39K | 6/3/2026 | View on chart |
| ADCT | ▲ Buy | Grant | 45,000 | $0 | 6/1/2026 | View on chart |
| CAH | ▲ Buy | Grant | 1,067 | $0 | 11/5/2025 | View on chart |
| ADCT | ▼ Sell | Tax Withholding | 12,600 | $45K | 6/13/2025 | View on chart |
| ADCT | ▲ Buy | Grant | 40,000 | $0 | 6/3/2025 | View on chart |
| CAH | ▲ Buy | Grant | 1,730 | $0 | 11/6/2024 | View on chart |
| ADCT | ▼ Sell | Open Market | 6,995 | $20K | 6/17/2024 | View on chart |
| ADCT | ▲ Buy | Grant | 40,000 | $0 | 6/13/2024 | View on chart |
| CAH | ▲ Buy | Grant | 1,288 | $0 | 3/15/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Tango Therapeutics to Present Phase 1/2 Vopimetostat Data at ESMO 2026
Tango Therapeutics announced that it will share updated results from its Phase 1/2 study of vopimetostat combined with daraxonrasib or zoldonrasib in patients with MTAP‑deleted/RAS‑mutated metastatic pancreatic cancer and non‑small cell lung cancer at the ESMO Congress 2026. The data focus on a targeted patient group and may provide insight into the early‑stage safety and activity of the combination therapies. The stock is currently near a long‑standing support level, which could be monitored as the conference proceeds.
Tango Therapeutics to Present Phase 1/2 Vopimetostat Data at ESMO 2026. Tango Therapeutics announced that it will share updated results from its Phase 1/2 study of vopimetostat combined with daraxonrasib or zoldonrasib in patients with MTAP‑deleted/RAS‑mutated metastatic pancreatic cancer and non‑small cell lung cancer at the ESMO Congress 2026. The data focus on a targeted patient group and may provide insight into the early‑stage safety and activity of the combination therapies. The stock is currently near a long‑standing support level, which could be monitored as the conference proceeds.